Reports Q3 revenue EUR 3.8M vs. EUR 1.37M last year. “We’re grateful for the strong support from investors and our partner Lilly in our $82.1 million equity financing last month, which further strengthens our financial position and extends our runway into mid-2027,” said Daniel A. de Boer, Founder and CEO of ProQR Therapeutics (PRQR). “As we approach the clinic with AX-0810 for cholestatic diseases, we look forward to sharing updates on this program, including preclinical data, clinical trial design, and biomarkers that will be assessed, along with pipeline highlights at our Investor and Analyst Event in December. With our Axiomer RNA editing platform, a differentiated pipeline, a productive partnership, and the leading IP position in the field, we remain focused on advancing transformative therapies for the unmet needs of patients.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PRQR:
- PRQR Earnings this Week: How Will it Perform?
- Trade Desk downgraded, First Solar upgraded: Wall Street’s top analyst calls
- ProQR Therapeutics upgraded to Strong Buy from Outperform at Raymond James
- ProQR Announces Major Share Offering Agreement
- Largest borrow rate increases among liquid names
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
